

KLEMA CATHY  
Form 4  
August 01, 2012

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287  
Expires: January 31, 2005  
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
KLEMA CATHY

2. Issuer Name and Ticker or Trading Symbol  
WATSON PHARMACEUTICALS  
INC [WPI]

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

(Last) (First) (Middle)

3. Date of Earliest Transaction (Month/Day/Year)  
07/31/2012

Director  10% Owner  
 Officer (give title below)  Other (specify below)

300 CENTRAL PARK WEST

(Street)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

NEW YORK, NY 10024

(City) (State) (Zip)

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

| 1. Title of Security (Instr. 3)  | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Ownership (Instr. 4) |
|----------------------------------|--------------------------------------|--|--------------------------------|---|---|--|-----------------------------------|
|                                  |                                      |  | Code                           | V   | Amount  | (A) or (D)   | Price                             |
| Common Stock, par value \$0.0033 | 07/31/2012                           |  | M                              |   | 11,700  | A  | \$ 44.14                          |
| Common Stock, par value \$0.0033 | 07/31/2012                           |  | M                              |   | 5,000   | A  | \$ 30.12                          |
| Common Stock, par value \$0.0033 | 07/31/2012                           |  | M                              |   | 5,000   | A  | \$ 29.03                          |

Edgar Filing: KLEMA CATHY - Form 4

|   |            |   |        |   |                           |                       |   |
|---|------------|---|--------|---|---------------------------|-----------------------|---|
| Common<br>Stock, par<br>value<br>\$0.0033 | 07/31/2012 | S | 11,700 | D | \$<br>78.38<br><u>(1)</u> | 37,732                | D |
| Common<br>Stock, par<br>value<br>\$0.0033 | 07/31/2012 | S | 5,000  | D | \$<br>78.38<br><u>(1)</u> | 32,732                | D |
| Common<br>Stock, par<br>value<br>\$0.0033 | 07/31/2012 | S | 5,000  | D | \$<br>78.38<br><u>(1)</u> | 27,732 <sup>(2)</sup> | D |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of<br>Derivative<br>Security<br>(Instr. 3)        | 2. Conversion<br>or Exercise<br>Price of<br>Derivative<br>Security | 3. Transaction Date<br>(Month/Day/Year) | 3A. Deemed<br>Execution Date, if<br>any<br>(Month/Day/Year) | 4. Transaction<br>Code<br>(Instr. 8) | 5. Number of<br>Derivative<br>Securities<br>Acquired (A)<br>or Disposed of<br>(D)<br>(Instr. 3, 4,<br>and 5) | 6. Date Exercisable and<br>Expiration Date<br>(Month/Day/Year) | 7. Title and Amount<br>Underlying Security<br>(Instr. 3 and 4) | Amount<br>or<br>Number<br>of S |  |
|--|--|---|---|--------------------------------------|--|--|--|--------------------------------|--|
|  |  |   |   | Code                                 | V (A) (D)  | Date<br>Exercisable  | Expiration<br>Date   | Title                          |  |
| Non-Qualified<br>Options to<br>Purchase<br>Common<br>Stock | \$ 44.14   | 07/31/2012                              |   | M                                    | 11,700   | 05/20/2005 03/26/2014  | Common<br>Stock, par<br>value<br>\$0.0033                      | 11                             |  |
| Non-Qualified<br>Options to<br>Purchase<br>Common<br>Stock | \$ 30.12   | 07/31/2012                              |   | M                                    | 5,000  | 06/29/2006 06/29/2015  | Common<br>Stock, par<br>value<br>\$0.0033                      | 5,                             |  |
| Non-Qualified<br>Options to<br>Purchase<br>Common<br>Stock | \$ 29.03   | 07/31/2012                              |   | M                                    | 5,000  | 05/05/2007 05/05/2016  | Common<br>Stock, par<br>value<br>\$0.0033                      | 5,                             |  |

## Reporting Owners

| Reporting Owner Name / Address                             | Relationships |           |         |       |
|--|---------------|-----------|---------|-------|
|  | Director      | 10% Owner | Officer | Other |
| KLEMA CATHY<br>300 CENTRAL PARK WEST<br>NEW YORK, NY 10024 | X             |           |         |       |

## Signatures

/s/CATHERINE M.  
KLEMA

08/01/2012

  Signature of Reporting Person                      Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).  
 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$78.28 to \$78.52, inclusive. The reporting person undertakes to provide to Watson Pharmaceuticals, Inc., any security holder of Watson Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (1) to this Form 4.
- (1) Includes shares of restricted stock issued pursuant to the Fourth Amendment and Restatement of the 2001 Incentive Award Plan of Watson Pharmaceuticals, Inc.
- (2)

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.